Scancell Holdings Plc Directorate Changes (0930E)
26 October 2022 - 5:00PM
UK Regulatory
TIDMSCLP
RNS Number : 0930E
Scancell Holdings Plc
26 October 2022
26 October 2022
Scancell Holdings plc
("Scancell" or the "Company")
Directorate Changes
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies, today announces that John Chiplin intends to
resign his role as Executive Chairman and Non-Executive Director of
the Company for personal reasons but is staying on for an interim
period until a new Chair is appointed.
The Board has initiated a formal search for a new Chair and a
further announcement regarding details and timings will be made in
due course.
The Board also announces that Richard Goodfellow intends to
retire as Non-Executive Director of the Company and will not seek
re-election at the upcoming AGM.
The Board also confirms that they have appointed Susan Clement
Davies, an independent Non-Executive Director and Chair of the
Audit Committee, as Deputy Chair.
Prof Lindy Durrant, Chief Executive Officer, Scancell ,
commented: "The Board wishes to express its sincere thanks to John
for his excellent stewardship, support and enthusiasm throughout
his tenure as Executive Chairman. We are pleased that he will be
with us for a while longer.
"The Board also wishes to express its gratitude to Richard. As
Scancell's co-founder and until 2017 its CEO Richard has been
instrumental in Scancell's evolution. His unfailing support and
vision has been an inspiration to everyone involved at Scancell. We
wish Richard a long and happy retirement."
Dr John Chiplin, Executive Chairman, Scancell, commented : " It
has been a privilege and pleasure to have chaired the Scancell
Board over the last six years. As I plan to hand over the reins to
a successor, I will be leaving the Company well financed, with an
exciting product pipeline, a strong management team and a
high-quality shareholder base. I certainly will continue to remain
a supportive shareholder."
Dr Richard Goodfellow, Non-Executive Director, Scancell,
commented : " Scancell was founded over 20 years ago from Lindy's
innovative and visionary research and it has been a privilege to
have been involved in the evolution of the Company from a few
highly original ideas to an established biotechnology company with
three products in clinical trials and its first commercially
significant deal. I remain hugely optimistic about the future of
the Company and I am sure that the best is yet to come ."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated
Adviser and Joint Broker)
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking) +44 (0) 20 7710 7600
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABKPBDOBDDBKB
(END) Dow Jones Newswires
October 26, 2022 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024